Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-3150 (Esaxerenone) in Hypertensive Patients with Type 2 Diabetes and Albuminuria
jRCT2080223238Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of esaxerenone in hypertension (HTN), type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Change in sitting systolic blood pressure from baseline to end of treatment and Change in sitting diastolic blood pressure from baseline to end of treatment. Started Jun 2016; status: completed.
02
Drugs
esaxerenone
03
Conditions
hypertension (HTN)type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on jRCT2080223238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223238.